Taking Innovation to Market
Ask about Knowledge at Wharton
Episode Description
Technology transfer is a "lottery business," according to Benjamin Soffer, manager of T3, the commercialization arm of Technion -- the Israel Institute of Technology in Haifa. "You never know which technology will actually make the difference," he says, "so you try to buy as many tickets as possible." In an interview with Israel Knowledge@Wharton, Soffer discussed T3's philosophy, process and some of its recent success stories.
Read the full transcriptHide the full transcript
- [Music] [Music] Hi Ben, thanks so much for being with us today. Thanks so much for having me.
- Now, first of all, we would like you to talk a little bit about um what is the mission of Techneon technology transfer
- and can you give us kind of a brief overview of your operations? Well, the technon technology transfer is the tech
- transfer company of the technon. So our role is to make sure that innovations that are developed within the technon
- finds their way to the marketplace. Um in today's day and age you know it's very imperative it's very
- important for university not just to do research not just to do teaching but to do technology transfer. And uh at the
- technon we have come to realize that universities that will not be able to impact the marketplace by creating jobs
- by engaging the community by building companies to some extent will become irrelevant.
- And how does the technology transfer process at techneon work? I mean how do you go about identifying research that
- has commercial potential and then what are the stages stages of actually turning that into a product or a service
- that people can buy on the market? Oh, that's a very good question. The the main mission, I think the number one
- mission is to increase the level of openness of the institution to commercialization because you have to
- understand and the at the end of the day people come for a university like the technon which is you know considered the
- uh the MIT of of Israel certainly if not the Middle East um they come to do you know cutting edge research and the techn
- is considered among the top 10 university in the world. So first of all you you need to increase the level of
- openness of the researchers to commercialization. So this is number one. Then you know the idea is how you
- bring the innovations that you produce to the marketplace. How do you increase the awareness and how do you create the
- opportunities for this innovations to find their way to the marketplace? Now I mean when you have several good ideas
- that could lead to commercial products what process do you use? I mean to kind of figure out I mean of all the
- wonderful research going on at the university. I mean what kind of process do you go through to figure out you know
- what are the things that are maybe going to be most likely to sort of have that direct path to commercial research or
- even maybe ones that are a little more of a twisting path like what is sort of the right projects to focus on?
- Well you know you can tell a lot about the nation by looking at your culture heroes. You know let's let's take a
- quick look at the United States. Who are the culture heroes? Of course you have Bill Gates and you know Steve Jobs and
- and and you also have the Hollywood players and the politicians in Israel. For many years the culture heroes so to
- speak were the generals you know people like Mosha Dian and Aric Shaon and others. But in recent years you know
- people like Gil Shvved people like Yosi Valdi you know the pioneers in the ITC industry certainly became the new
- culture heroes of of Israel. Now many of them are graduates of the technon. You may be surprised to learn that out of
- the 120 Israeli or Israeli related companies on NASDAQ 70% of the CEOs or CEOs of these companies are graduates of
- the Technon. So our main focus in order to commercialize the technologies is finding the right person to take that
- technology to the market. So we have developed a very elaborate you know what we call EIR entrepreneur in residence
- program whereby we try to marry a very strong entrepreneur with a very strong technology and what we do is we use this
- entrepreneurs as agents of the marketplace within the campus of the technon and know what have you found I mean with
- having the entrepreneurs working together with the researchers what do you find that the two are able to learn
- from each other as they're kind of in this partnership You know this is a very interesting dialogue because you know at
- academic settings many of the innovations are technologies looking for a problem but you if you have the
- qualified you know the trained eye of a very strong entrepreneur out of this dialogue you know some most some of the
- most brilliant things can can come out and we have witnessed time and again and now what do you mean do you find that
- also the researchers I mean the entrepreneurs are learning some things from the researchers as always.
- Absolutely. And now one of the best known examples of tech transfer um has been at Techneon has been the
- development of a treatment for Parkinson's disease called Azle. I hope I'm pronouncing that right. Correct. And
- that was developed based on research at Techneon by again hoping I'm pronouncing
- it right um Musa Udim and John Finnberg in collaboration with Tiva Pharmaceuticals. Could you take us
- through the process of how that came about? Well, you know, first maybe we should
- step take a, you know, a quick step uh step back. In Israel, we have, you know, uh maybe four leading universities. The
- Technneon certainly uh one of them, the Hebrew University, and the Vitzman Institute. All three leading
- universities in Israel, Technneon, Hebrew Universities, and the Vitman have at least one FDA approved drug in the
- market. And the technon is you know belongs to this quite distinguished club of universities that were able to
- develop a drug and take it to uh to the marketplace. Now you have to remember this is the process started about 20 25
- years ago when the funding from sources like the NIH and others were quite quite
- more available. So the research was done at the laboratory of professor Musay Yudim and
- John Fineberg and later on it was licensed in a pure straightforward licensing deal which as opposed to deals
- that are done today was about four pages deal and up until today uh you know it serves us very well. Now the and this is
- again a good demonstration of how long it takes to develop the drug that you know is developed at the benchtop in a
- university setting until it reaches the marketplace. And people don't always realize that this is a very long and
- tedious process. So when you ask me why isn't it happening for example through VCs and why was it directly licensed to
- a to a commercial company then I would tell you that this is the right process for for drug developments because
- between a university and the venture capital war there's some sort of a synchronization problem because we
- operate in a window that could easily be 10 11 12 years long and as we see here even 20 while the VCs operate in a much
- shorter window of five, six, seven years. And this gap has to be filled and the question is who will fill the gap?
- And if it's not the government, it has to be industry. Otherwise, all this investment will be lost. Not the
- government, it has to be industry. Otherwise, all this investment will be lost. Now, could you give us some other more
- examples of research at Techneon that was successfully turned into commercial products and maybe talk a little more
- about Absolutely. trying to figure out, you just mentioned sort of go through commercial like a commercial company
- versus VCs like some of the different paths maybe you've taken to try and get the get the product to market.
- Absolutely. We are, you know, uh although we are predominantly an engineering school, the Techneon has
- made some major breakthroughs in in medical devices. So in all the area of robotic aided surgery the the technon
- has won considerable fame. Some of the companies that we uh boast in are companies like mazo which is in the
- business of spine fusion. About 3% of the procedures that are done today when you do spine fusion the doctor drills
- right into the spine cord. What mazor allows using a robotic a surgery is first to see and then only to do the
- drill. This is a company by professor mushes shwam. Another company that we started with professor masham is a
- company called kurindus. Corindus is in the business of remote catheterization. I have a brother, he's an interventional
- cardiologist in Mount Sinai in New York and he walks a little bit bent and this is because of the heavy lead suits that
- they need to wear while operating. So imagine for a minute that you sit in a remote location, it can be the adjacent
- room or it can be the the another continent and using joystick you guide the guide wider the guide wire in the
- body of the patients and do the procedure remotely. And this is what is done by a company like Corindas.
- Now Technon companies have raised just in year 2012 close to $60 million. In year 2011 it was again close to $50
- million. In the last three years they have raised close to $150 million which in Israeli terms is quite significant.
- And this is a demonstration of the validation of the marketplace of industry in the innovation that is
- coming out of the technia. Now often I mean when you're talking about innovation or really anything I mean you
- often have for every one success there's probably you know multiple failure failures you can talk about and
- sometimes you learn more from those than maybe some of the successes. So could you talk about maybe what are some of
- what have been some of's most instructive failures and what you've learned from them?
- Well, at the end of the day, what we have learned that the level of risk at which we are talking is extremely
- extremely high. But the because the level of unknowns on the technology level on the marketing level is
- extremely high. And this is why and this is what something that we have learned that in order to successful successfully
- launch u an enterprise a company you need a very very strong entrepreneur. We see starting a business as sending a
- spacecraft to space. The first 10 minutes that you detach yourself from gravity consume 80 90% of the energy of
- the gasoline in in in this huge spacecraft and you have to have the person the right person to inject the
- energy into the process and this person is the entrepreneur. Now many think that
- because it's a university and a you know a high-risisk technology you can so to speak do well with a less experienced
- entrepreneur but it's right on the contrary to commercialize a technology from a university you need a very strong
- entrepreneur that can you know relay to the marketplace raise the necessary capital but at the same time talk at the
- eye level with a professor. So if you ask me what is the number one lesson is have a very very strong team that knows
- how to work together. Now how would you say um Tiffanyon's technology transfer operation and the
- way that you go about doing this compares with other Israeli institutions such as the Weisman Institute and then
- also US institutions like MIT or Stanford or even here at Wharton? Well, this is again an an excellent question
- because you know this is part of the metrics that we use to measure ourself to ask ourselves are we successful. So
- first of all let's you know compare apples to apples you know take the research budget the research budget of
- of the technon is something like $70 million. The research budget of a university like MIT including Lincoln
- lab is $1.4 billion. The research budget of Stanford is $700 million. So if you just use the income metrics compared to
- the investment that you make in research, the Techon is doing extremely well because we generate today close to
- $25 million directly from commercialization. So this is either royalties, income, equity or dividend.
- Now if you compare it to what MIT is doing and other leading university, we are doing extremely well.
- But the point is that as a university this is not the only metrics that you should use. I mean for us the income
- certainly is critical but you need to see the economic development that is done around the technon in a city like
- Kyifa. How many companies have established their presence surrounding the technon in order to tap into the
- human capital and the resources available at the technon. So companies like Google, uh, Phillips, Microsoft all
- have and are operating significant R&D centers at a 10-minut drive from the technon campus. So it's not just how
- much, but it's more like what kind of domino effect does each one create like this goes to this and this. You are
- absolutely right, Rachel. Again, the issue is not to maximize every deal that we do. So we do not try to extract the
- most economic value from the deals that we do but we try to do as many deals as possible. In a way we view technology
- transfer as a lottery business because honestly you never really know which technology will actually make the
- difference be the par the paradigm shift. So you try to buy as many tickets as possible. And if you ask me what is
- the philosophy that makes T3 my unit unique is that we have adopted a philosophy that if technon is a huge
- harbor we are the tagbo. Our role is to make sure that the research done at the technon will find its way out of the
- port of the technon as quickly and as effectively as possible. We are not a gateway and this is something that is
- changing and I think it's very important for the industry to understand. Now could you talk a little bit about I mean
- what are some of your top priorities for 2013 and then also kind of looking beyond that a little bit. Well we are
- putting a huge emphasis now on stem cells. Just a couple of months ago, we have started a company called Axelta
- within Amit, which is an internal incubator that we started with the help of uh Alfred Man, you know, uh very
- prominent and successful businessmen here in the United States that have started many companies and Excela is
- exactly in the business of drug development, drug screening. We all realize now that the drug development
- and the drug screening is broken. So what Axela is doing at the end of the day it will be to help do clinical
- trials on a chip as opposed you know to the way clinical trials are done today. It's a stem cells company developing the
- pick and shovels of the industry of the stem cells uh stem cells research and stem cells uh
- development. Ben, thank you so much for talking with us today. My pleasure. Thank you, Rachel.
- [Music]
Brief Summary
Ben discusses Techneon technology transfer, its mission, successes like Azle, and future focus on stem cell research.
Key points
- The Role of Techneon. Techneon focuses on technology transfer to ensure innovations reach the marketplace.
- Cultural Heroes of Israel. The shift from military leaders to tech entrepreneurs as cultural icons in Israel.
- Successful Drug Development. Techneon has developed an FDA-approved drug for Parkinson's disease, showcasing its impact.
Episode highlights
- The Role of TechneonTechneon focuses on technology transfer to ensure innovations reach the marketplace.“It's imperative for universities to engage in technology transfer.”0:49Mar 4, 2013
- Cultural Heroes of IsraelThe shift from military leaders to tech entrepreneurs as cultural icons in Israel.“In recent years, IT pioneers became the new culture heroes of Israel.”3:14Mar 4, 2013
- Successful Drug DevelopmentTechneon has developed an FDA-approved drug for Parkinson's disease, showcasing its impact.“Techneon belongs to a distinguished club of universities that developed a drug.”5:30Mar 4, 2013
Tension
40/ 100Low tension





